Literature DB >> 12772879

Challenge and opportunities in the treatment of gastric cancer.

Tetsuo Taguchi1, James Bishop.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12772879     DOI： 10.1007/s10120-002-0206-3

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  14 in total

1.  Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.

Authors:  A M Murad; A Petroianu; R C Guimaraes; B C Aragao; L O Cabral; A O Scalabrini-Neto
Journal:  Am J Clin Oncol       Date:  1999-12       Impact factor: 2.339

Review 2.  Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.

Authors:  J A Ajani; J Baker; P W Pisters; L Ho; B Feig; P F Mansfield
Journal:  Oncology (Williston Park)       Date:  2001-03       Impact factor: 2.990

3.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

4.  Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.

Authors:  C C Earle; J A Maroun
Journal:  Eur J Cancer       Date:  1999-07       Impact factor: 9.162

5.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Authors:  J A Wils; H O Klein; D J Wagener; H Bleiberg; H Reis; F Korsten; T Conroy; M Fickers; S Leyvraz; M Buyse
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

6.  Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.

Authors:  K Shirao; Y Shimada; H Kondo; D Saito; T Yamao; H Ono; T Yokoyama; H Fukuda; M Oka; Y Watanabe; A Ohtsu; N Boku; T Fujii; Y Oda; K Muro; S Yoshida
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

7.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

8.  Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.

Authors:  Y H Kim; S W Shin; B S Kim; J H Kim; J G Kim; Y J Mok; C S Kim; H S Rhyu; J H Hyun; J S Kim
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

9.  FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

Authors:  D Kelsen; O T Atiq; L Saltz; D Niedzwiecki; D Ginn; D Chapman; R Heelan; C Lightdale; V Vinciguerra; M Brennan
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.

Authors:  J Wils; H Bleiberg; O Dalesio; G Blijham; N Mulder; A Planting; T Splinter; N Duez
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.